Dll3 - delta like canonical Notch ligand 3 Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 114125

Summary

Enables Notch binding activity. Involved in central nervous system development; negative regulation of Notch signaling pathway; and regulation of neurogenesis. Predicted to be integral component of membrane. Human ortholog(s) of this gene implicated in dysostosis and spondylocostal dysostosis. Orthologous to human DLL3 (delta like canonical Notch ligand 3). [provided by Alliance of Genome Resources, Apr 2022]

Dll3 Products (1)

mRNA Protein Name
NM_053666.2 NP_446118.2 delta-like protein 3 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
Molecular Function GO Annotation Evidence References Source
enables Notch binding IPI
IPI: Inferred from physical interaction
16144902 RGD
Biological Process GO Annotation Evidence References Source
involved in negative regulation of Notch signaling pathway IDA
IDA: Inferred from direct assay
16144902 RGD
involved in negative regulation of astrocyte differentiation IDA
IDA: Inferred from direct assay
16144902 RGD
involved in positive regulation of neurogenesis IDA
IDA: Inferred from direct assay
16144902 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

delta-like protein 3

  • delta3

  • drosophila Delta homolog 3

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99575 Tarlatamab Inhibitor 99.77% Unkown

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-132257 Rovalpituzumab tesirine Inhibitor 97.47% Phase 3
Inhibitory Antibodies (6)
Cat. No. Product Name Effect
Purity Phase
HY-P99043 Rovalpituzumab Inhibitor 99.84% Phase 3
HY-P990932 Obrixtamig Inhibitor 99.9% Phase 3
HY-P991731 Alveltamig 98% Phase 3
HY-P990920 Gocatamig Inhibitor ≥99.0% Phase 2
HY-P991016 Peluntamig 99.9% Phase 2
HY-P990981 Clesitamig 99.78% Phase 1

Pre-clinical Phase

Bioactive Molecules (6)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-W1126504 ETN029 Ligand 99.91% Unkown
HY-164729 FZ-AD005 97.27% Unkown
HY-159072 Mal-Val-Ala-PAB-N(SO2Me)-Exatecan 98.84% Unkown
HY-RS03809 DLL3 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS16720 Dll3 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23156 Dll3 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (4)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P990104 Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) Inhibitor 99.39% Unkown
HY-P990896 FZ-A038 99.15% Unkown
HY-P992148 Zocilurtatug Inhibitor 99.50% Unkown
HY-P991173 AMG-119 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Dll3 NCBI NCBI:10683